AR and prostate cancer: Several clinical trials are currently underway examining the efficacy of various inhibitors of mTOR signaling.42, 43, 65, 66 However, at this time the use of inhibitors of mTOR signaling in patients has been met with limited success, perhaps indicating the presence of redundant mechanisms.66 Our results here suggest that metabolism through the pentose phosphate pathway may be a relevant marker for a subset of prostate cancers and that blocking the flux through this pathway may serve as an alternative downstream target to inhibitors of mTOR and AR.